We also recommend that patients be followed up to investigate the prognostic value of lipocalin 2 in breast cancer patients, which is essential to determine its potential as a future therapeutic target for some aggressive subtypes of breast cancer. This evidence concerns the gene LCN2 and breast carcinoma.